Suppr超能文献

[使用专用器械进行经导管主动脉瓣置入术治疗主动脉反流。一项系统评价]

[[TAVI for aortic regurgitation using dedicated devices. A systematic review]].

作者信息

Hassan Ahmed, Abdelshafy Mahmoud, Diab Rehab Adel, Wienemann Hendrik, Adam Matti, García Santiago, Saad Marwan, Abdelghani Mohammad

机构信息

Department of Cardiology, Suez Medical Complex, Suez, Egipto Department of Cardiology Suez Medical Complex Suez Egipto.

Cardiology Department, Faculty of Medicine, Al-Azhar University, Cairo, Egipto Cardiology Department Faculty of Medicine Al-Azhar University Cairo Egipto.

出版信息

REC Interv Cardiol. 2025 Feb 24;7(1):29-43. doi: 10.24875/RECIC.M24000480. eCollection 2025 Jan-Mar.

Abstract

INTRODUCTION AND OBJECTIVES

Transcatheter aortic valve implantation (TAVI) for pure aortic regurgitation is challenging due to inadequate device anchoring and increased risks of device embolization and paravalvular regurgitation (PVR). This study aimed to review the safety and efficacy of TAVI for aortic regurgitation with devices specifically designed for this indication.

METHODS

A comprehensive search of PubMed, Web of Science, Cochrane Library, and major conference archives up to April 2024 identified 143 unique results based on predefined criteria.

RESULTS

Fifteen studies (n = 788 patients) were included, with J-Valve used in 357 patients and JenaValve in 431. Men represented 51% of the cohort, with a mean age of 74.7 ± 8.8 years and an STS-PROM score of 5.8 ± 4.9%. Transapical and transfemoral access routes were used in 62.7% and 37.3% of patients, respectively. Overall, procedural success was achieved in 95.9% of cases; surgical conversion was required in 1.8%, device migration/embolization occurred in 3.2%, and a second valve (in-valve) was required in 2.0% of patients. At 30 days, 95.5% of patients were alive, and device success was reported in 93.3% of cases. Mild PVR was observed in 18.0% of patients, moderate-to-severe PVR in 1.7%, and permanent pacemaker implantation (PPI) was required in 13.0%. In studies focusing on transfemoral procedures (all using JenaValve), the pooled estimates showed a procedural success rate of 97.8% (95%CI, 94.4-100), device success of 97.0% (95%CI, 94.8-99.2), 30-day mortality of 1.96% (95%CI, 0.20-3.72), moderate-to-severe PVR of 0.47% (95%CI, 0.00-1.47), and PPI requirement of 18.7% (95%CI, 13.9-23.4).

CONCLUSIONS

This systematic review of relatively small observational studies demonstrates the safety and favorable early outcomes of TAVI using J-Valve and JenaValve in patients with pure aortic regurgitation, especially when the transfemoral approach is used. Nevertheless, the need for PPI remains frequent.

摘要

引言与目的

由于器械锚定不充分以及器械栓塞和瓣周反流(PVR)风险增加,经导管主动脉瓣植入术(TAVI)治疗单纯主动脉瓣反流具有挑战性。本研究旨在回顾使用专门为此适应症设计的器械进行TAVI治疗主动脉瓣反流的安全性和有效性。

方法

截至2024年4月,对PubMed、科学网、Cochrane图书馆和主要会议档案进行全面检索,根据预定义标准确定了143个独特结果。

结果

纳入15项研究(n = 788例患者),其中357例患者使用J-Valve,431例使用JenaValve。男性占队列的51%,平均年龄为74.7±8.8岁,STS-PROM评分为5.8±4.9%。分别有62.7%和37.3%的患者采用经心尖和经股动脉入路。总体而言,95.9%的病例手术成功;1.8%的患者需要转为外科手术,3.2%发生器械移位/栓塞,2.0%的患者需要植入第二个瓣膜(瓣中瓣)。30天时,95.5%的患者存活,93.3%的病例报告器械植入成功。18.0%的患者观察到轻度PVR,1.7%为中重度PVR,13.0%的患者需要植入永久性起搏器(PPI)。在专注于经股动脉手术的研究中(均使用JenaValve),汇总估计显示手术成功率为97.8%(95%CI,94.4 - 100),器械植入成功率为97.0%(95%CI,94.8 - 99.2),30天死亡率为1.96%(95%CI,0.20 - 3.72),中重度PVR为0.47%(95%CI,0.00 - 1.47),PPI需求率为18.7%(95%CI,13.9 - 23.4)。

结论

这项对相对较小的观察性研究的系统评价表明,在单纯主动脉瓣反流患者中使用J-Valve和JenaValve进行TAVI具有安全性和良好的早期结果,尤其是采用经股动脉入路时。然而,PPI的需求仍然很常见。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bec8/12097355/dc198af84596/2604-7306-recic-7-1-29-en-gf1.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验